The Use of Real-World Data to Support the Assessment of the Benefit and Risk of a Medicine to Treat Spinal Muscular Atrophy

Tammy McIver, Muna El-Khairi, Wai Yin Yeung and Herbert Pang ()
Additional contact information
Tammy McIver: PD Data Sciences – Biostatistics, Roche Products Limited
Muna El-Khairi: PD Data Sciences – Biostatistics, Roche Products Limited
Wai Yin Yeung: PD Data Sciences – Biostatistics, Roche Products Limited
Herbert Pang: PD Data Sciences – Biostatistics, Genentech

A chapter in Real-World Evidence in Medical Product Development, 2023, pp 387-411 from Springer

Abstract: Abstract Spinal muscular atrophy (SMA) is a rare genetic neuromuscular disease that affects individuals with a broad age range and spectrum of disease severity, characterized by progressive loss of spinal motor neurons leading to debilitating and sometimes fatal muscle weakness. Therapeutic options had been limited for this patient population, and to address this unmet medical need, a series of studies on risdiplam (EVRYSDI®) began in 2016. Risdiplam has now been approved in more than 90 countries, including the United States and EU for the treatment of SMA. The approvals were primarily based on two pivotal clinical studies, FIREFISH and SUNFISH, designed to represent a broad spectrum of people living with SMA. FIREFISH is an open-label, single-arm study in infants aged 1–7 months with type 1 SMA. SUNFISH is a randomized, double-blind, placebo-controlled study in patients aged 2–25 years with type 2 and 3 SMA. Real-world data (RWD) from a combination of peer-reviewed publications and individual patients were used to support data interpretation and registration. Natural history data from publications were used to define performance criteria for key clinical endpoints in FIREFISH. RWD from individual patients were also used to perform a robust statistical comparison and contextualize the results from SUNFISH. In this chapter, we present a case study describing how RWD from publications and individual patient data were used to support the development of risdiplam, a medicine to treat SMA.

Keywords: External control; Natural history data; Real-world data; Real-world evidence; Risdiplam; Spinal muscular atrophy (search for similar items in EconPapers)
Date: 2023
References: Add references at CitEc
Citations:

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:sprchp:978-3-031-26328-6_20

Ordering information: This item can be ordered from
http://www.springer.com/9783031263286

DOI: 10.1007/978-3-031-26328-6_20

Access Statistics for this chapter

More chapters in Springer Books from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().